相似文献
1
Biochemical Testing in Neuroendocrine Tumors.
Endocrinol Metab Clin North Am. 2017 Sep;46(3):669-677. doi: 10.1016/j.ecl.2017.04.004. Epub 2017 Jun 12.
2
[Diagnostic and therapeutic opportunities in neuroendocrine tumors of the gastroenteropancreatic system].
Postepy Hig Med Dosw (Online). 2005;59:48-55.
3
Lung and digestive neuroendocrine neoplasms. From WHO classification to biomarker screening: Which perspectives?
Ann Endocrinol (Paris). 2019 Jun;80(3):163-165. doi: 10.1016/j.ando.2019.04.011. Epub 2019 Apr 11.
4
Laboratory tests for neuroendocrine tumours.
Q J Nucl Med. 2000 Mar;44(1):22-41.
5
Gastroenteropancreatic neuroendocrine (carcinoid) tumors in children.
Semin Pediatr Surg. 2014 Apr;23(2):91-5. doi: 10.1053/j.sempedsurg.2014.03.007. Epub 2014 Mar 14.
6
The Neuroendocrine Neoplasms of the Digestive Tract: Diagnosis, Treatment and Nutrition.
Nutrients. 2020 May 15;12(5):1437. doi: 10.3390/nu12051437.
7
Recent updates on grading and classification of neuroendocrine tumors.
Ann Diagn Pathol. 2017 Aug;29:11-16. doi: 10.1016/j.anndiagpath.2017.04.005. Epub 2017 Apr 13.
8
Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors.
Endocr Relat Cancer. 2007 Jun;14(2):221-32. doi: 10.1677/ERC-06-0074.
9
The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Endocrinol Metab Clin North Am. 2011 Mar;40(1):111-34, viii. doi: 10.1016/j.ecl.2010.12.001.
10
Neuroendocrine tumors of the gastro-entero-pancreatic system.
World J Gastroenterol. 2008 Sep 21;14(35):5377-84. doi: 10.3748/wjg.14.5377.
引用本文的文献
1
Dynamic nomogram for predicting the overall survival and cancer-specific survival of patients with gastrointestinal neuroendocrine tumor: a SEER-based retrospective cohort study and external validation.
Front Oncol. 2025 Jun 4;15:1594591. doi: 10.3389/fonc.2025.1594591. eCollection 2025.
2
Serum Concentrations of Selected Biological Factors as a Potential Tool for Detecting Recurrence in Endocrine Tumors-A Pilot Study.
J Clin Med. 2025 May 26;14(11):3732. doi: 10.3390/jcm14113732.
3
Unusual Cause of Wheezing in a Middle-Aged Woman: A Case Report.
Cureus. 2024 Aug 2;16(8):e66004. doi: 10.7759/cureus.66004. eCollection 2024 Aug.
4
Case Report: Carcinoid heart disease with severe tricuspid regurgitation and concomitant patent foramen ovale causing severe hypoxia.
Front Cardiovasc Med. 2024 Jan 18;10:1309929. doi: 10.3389/fcvm.2023.1309929. eCollection 2023.
5
An unusual presentation of accessory spleen mimicking a pancreatic neoplastic lesion in a splenectomized patient: A case report.
SAGE Open Med Case Rep. 2023 Sep 27;11:2050313X231201722. doi: 10.1177/2050313X231201722. eCollection 2023.
6
Non-specific Symptoms of Small Bowel Neuroendocrine Tumor and the Diagnostic Challenges: A Case Report.
Cureus. 2023 Jun 28;15(6):e41080. doi: 10.7759/cureus.41080. eCollection 2023 Jun.
7
Diagnostic Challenge of Small Bowel Neuroendocrine Tumor in a Young Female Patient.
Cureus. 2023 Apr 21;15(4):e37925. doi: 10.7759/cureus.37925. eCollection 2023 Apr.
8
Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future.
J Clin Med. 2022 Sep 21;11(19):5542. doi: 10.3390/jcm11195542.
9
Diagnosis and management of small bowel neuroendocrine tumors: A state-of-the-art.
World J Methodol. 2022 Sep 20;12(5):381-391. doi: 10.5662/wjm.v12.i5.381.
10
Pro-Gastrin-Releasing Peptide as a Marker of Small Cell Lung Cancer.
Bull Exp Biol Med. 2022 Jun;173(2):257-260. doi: 10.1007/s10517-022-05529-9. Epub 2022 Jun 23.
本文引用的文献
1
A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors.
Endocr Connect. 2014 Dec;3(4):215-23. doi: 10.1530/EC-14-0100. Epub 2014 Oct 14.
2
Molecular profiling for breast cancer: a comprehensive review.
Biomark Cancer. 2013 Oct 29;5:61-70. doi: 10.4137/BIC.S9455.
3
The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood.
PLoS One. 2013 May 15;8(5):e63364. doi: 10.1371/journal.pone.0063364. Print 2013.
4
A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
Pancreas. 2013 Apr;42(3):405-10. doi: 10.1097/MPA.0b013e318271c0d5.
5
Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors?
Pancreas. 2012 May;41(4):505-7. doi: 10.1097/MPA.0b013e318249a92a.
6
A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans.
Pancreas. 2012 May;41(4):508-11. doi: 10.1097/MPA.0b013e318243a0b6.
7
Limitations of Chromogranin A in clinical practice.
Biomarkers. 2012 Mar;17(2):186-91. doi: 10.3109/1354750X.2012.654511. Epub 2012 Feb 6.
8
The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Endocrinol Metab Clin North Am. 2011 Mar;40(1):111-34, viii. doi: 10.1016/j.ecl.2010.12.001.
9
The epidemiology of gastroenteropancreatic neuroendocrine tumors.
Endocrinol Metab Clin North Am. 2011 Mar;40(1):1-18, vii. doi: 10.1016/j.ecl.2010.12.005.
10
Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors.
PLoS One. 2010 Dec 30;5(12):e16010. doi: 10.1371/journal.pone.0016010.
Zotero 插件